Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript
Operator: Welcome to Acorda Therapeutics Third Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode.
Posts Tagged ‘NASDAQ:ACOR’
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q2 2023 Earnings Call Transcript
Operator: Welcome to Acorda Therapeutics Second Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q1 2023 Earnings Call Transcript
Operator: Welcome to Acorda Therapeutics First Quarter 2023 Financial and Business Update. [Operator Instructions].
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q4 2022 Earnings Call Transcript
Operator: Welcome to the Acorda Therapeutics Fourth Quarter and Year-End 2022 Financial and Business Update.
Hedge Funds Are Buying Acorda Therapeutics Inc (ACOR) Again
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive...
Is ACOR A Good Stock To Buy Now?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We...
Do Hedge Funds Love Acorda Therapeutics Inc (ACOR)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Hedge Fund and Insider Trading News: Bill Ackman, Marshall Wace, Greenlight Capital, Becton Dickinson and Co (BDX), On Track Innovations Ltd (OTIVF), and More
COPENHAGEN (Reuters) - Hedge fund Marshall Wace is betting on Danske Bank (DANSKE.CO) shares falling after taking a short position in the Danish lender of 0.5% of issued shares...
Hedge Funds Are Getting Burned By Acorda Therapeutics Inc (ACOR)
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider...
Were Hedge Funds Right About Dumping Acorda Therapeutics Inc (ACOR)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th.
Here’s What Hedge Funds Think About Acorda Therapeutics Inc (ACOR)
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong.
Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter.
Hedge Fund and Insider Trading News: Israel Englander, Omega Advisors, Jabre Capital, Red Lion Hotels Co. (RLH), Amkor Technology, Inc. (AMKR), and More
(Bloomberg) -- It has been yet another year to forget in the world of hedge funds.
Hedge Fund and Insider Trading News: David Tepper, Soros Fund Management, Lixte Biotechnology Holdings Inc (LIXT), Acorda Therapeutics Inc (ACOR), Achaogen Inc (AKAO), and More
Hedge fund titan David Tepper said Thursday the Federal Reserve is sending the market a message, and it’s not a good one.
Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed...
Hedge Fund and Insider Trading News: John Paulson, Ray Dalio, International Flavors & Fragrances Inc (IFF), KAR Auction Services Inc (KAR), Second Sight Medical Products Inc (EYES), and More
(Reuters) - Activist investor John Paulson’s hedge fund on Thursday said it would urge Detour Gold Corp (DGC.TO) to call a special shareholder meeting to replace a majority ...
13D Filing: Scopia Capital and Acorda Therapeutics Inc (ACOR)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent...
Hedge Fund and Insider Trading News: Och-Ziff Capital Management, Jana Partners, Intrexon Corp (XON), Legacy Reserves LP (LGCY), and More
(Reuters) - Och-Ziff Capital Management on Tuesday named Robert Shafir as its new chief executive officer, succeeding Dan Och after a battle over who will run the hedge fund firm...
Hedge Fund and Insider Trading News: Elliot Management, Brevan Howard, Acorda Therapeutics Inc (ACOR), Cognizant Technology Solutions Corp (CTSH), and More
Elliott Management Corp., the hedge fund founded by billionaire Paul Singer, has built a stake in Sky Plc as shareholders prepare to vote on 21st Century Fox Inc.’s 11.7-billion...
Market Movers Today: Nike Inc (NKE), Forward Industries, Inc. (FORD), International Business Machines Corp (IBM), and More
Shares of Nike (NYSE:NKE) rose over 3% Friday morning following an upgrade by Wedbush to Outperform (from Neutral) with a new price target of $74.00 (from $57.00).
13D Filing: Scopia Capital and Acorda Therapeutics Inc (ACOR)
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d...
13D Filing: Scopia Capital and Acorda Therapeutics Inc (ACOR)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent...
13G Filing: Partner Fund Management and Acorda Therapeutics Inc (ACOR)
You can access the original SEC filing by clicking here.
Here’s What Is Happening In Financial Markets Today?
“Wall Street stocks on Monday were aiming to start the second quarter with tepid gains.
Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)
In order to ensure an extension of Ampyra’s protection to 2026, Acorda Therapeutics Inc (NASDAQ:ACOR) must fight off competition from competitors such as Roxane, Teva Pharmaceutical...
Can Acorda Therapeutics Inc (ACOR) Give Eli Lilly And Co (LLY) A Run For Its Money In Migraine Drug Market?
Acorda Therapeutics Inc (NASDAQ:ACOR) inhaled migraine candidate CVT-427 is seen by Janney analyst Ken Trbovich as likely to give Eli Lilly and Co (NYSE:LLY) severe competition...
Acorda Therapeutics Inc (ACOR) Continues To Fall From Favor With Top Investors
Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to...
Biotech Movers And Shakers: Mast Therapeutics, Inc. (MSTX) And Acorda Therapeutics Inc (ACOR)
To find a winner in the biotech space this week, all you’d need to do is throw a dart at a basket of micro-caps.
Skypeople Fruit Juice Inc. (SPU), Lands’ End Inc. (LE) & Others: Why These Losers Are Dragging Down the Market
The markets continue to trade down in anticipation of the upcoming OPEC meeting.
Why Does The Smart Money Like Acorda Therapeutics?
Acorda Therapeutics Inc (NASDAQ:ACOR) is a $1.11 billion biotechnology company that develops and commercializes novel therapies for neurological disorders.
Two Big Parkinson’s Updates From Adamas Pharmaceuticals Inc (ADMS) And Acorda Therapeutics Inc (ACOR)
We just got a couple of updates in the Parkinson’s space, and both have the potential to serve up some volatility in the market capitalisations of the companies in question.
Should You Buy Acorda Therapeutics Inc (ACOR)?
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals.
These Oil and Biotech Stocks Are in the Crosshairs of Elite Investors
While many hedge funds are still preparing their third quarter filings with the SEC, providing the main ingredients for our delectable small-cap investment strategy, some managers...
Kyle Bass’ War Against Pharmaceutical Companies Goes On While The Masses Overlook China’s Real Problem
Those who seek to profit from shorting strategies should keep a close eye on Kyle Bass’ war against the pharmaceutical industry.
Acorda Therapeutics Inc (ACOR)’s Shares Jump After Dismissal Of Patent Challenge From Hedge Fund Manager Kyle Bass
The shares of Acorda Therapeutics Inc (NASDAQ:ACOR) are trading 13.16% higher today after the dismissal of a patent challenge against the company.
Nektar Therapeutics (NKTR): Insiders Aren’t Crazy About It But Hedge Funds Love It
Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment vehicles of a forgotten age.
Acorda Therapeutics Inc (ACOR): Insiders Aren’t Crazy About It But Hedge Funds Love It
To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age.
Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)
If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.
Alnylam Pharmaceuticals, Inc. (ALNY): Insiders Aren’t Crazy About It But Hedge Funds Love It
If you were to ask many market players, hedge funds are seen as useless, outdated financial tools of a period lost to current times.
Alnylam Pharmaceuticals, Inc. (ALNY): Here’s What The Smart Money Thinks
Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the right investment to pursue these days? Hedge funds are taking a bullish view.
Is Nektar Therapeutics (NKTR) Going to Burn These Hedge Funds?
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds' portfolio at the end of March.
Is Acorda Therapeutics Inc (ACOR) Going to Burn These Hedge Funds?
Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds' portfolio at the end of March. ACOR has experienced a decrease in hedge fund sentiment lately.
This Metric Says You Are Smart to Buy Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds' portfolio at the end of March.
Idenix Pharmaceuticals Inc (IDIX), Alnylam Pharmaceuticals, Inc. (ALNY) & 3 Small Biotechs Top Hedge Funds Are Investing In
Small biotech companies have great investment potential if you can identify them properly.
Vertex Pharmaceuticals Incorporated (VRTX), Gilead Sciences, Inc. (GILD): The Week, Biotech – Part Two
As I mentioned previously in Part 1, it was an incredibly busy week for the biotech sector.
Biopharma News: Theravance Inc (THRX), VIVUS, Inc. (VVUS), Amgen, Inc. (AMGN)
Editor's Note: Related tickers: Theravance Inc (NASDAQ:THRX), VIVUS, Inc. (NASDAQ:VVUS), Amgen, Inc.
Acorda Therapeutics Inc (ACOR): Insiders Are Dumping, Should You?
Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds' portfolio at the end of the fourth quarter of 2012.
